通过miRNA-374准PGC-1α同时改善β细胞功能障碍并抑制肝脏葡萄糖过度生产
Ji-Won Kim1,2, Joonyub Lee1, Young-Hye You1
1Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Diabetes & metabolism journal
|November 3, 2025
概括
微RNA-374 (miR-374) 通过调节PGC-1α表达,有效降低血糖. 通过改善胰腺小岛功能和减少肝脏胰岛素耐药性,提供miR-374的exendin-4涂层的阴离子脂粒显示出治疗2型糖尿病的前景.
科学领域:
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 2型糖尿病 (T2DM) 的高血糖与胰腺小岛和肝脏的基因表达改变有关.
- 过氧体增殖器激活受体 γ 协作活化剂-1 (PGC-1α) 是葡萄糖代谢和胰岛素分泌的关键调节剂,其失调有助于T2DM.
- 微RNA (miRNA) 在转录后基因调节中起着至关重要的作用,并与代谢性疾病有关.
研究的目的:
- 研究miR-374在调节胰腺小岛和肝脏中的PGC-1α表达中的作用.
- 评估miR-374在改善高血糖和改善胰腺β细胞功能和T2DM中的肝脏胰岛素抵抗方面的治疗潜力.
- 开发miR-374的有效输送系统,以提高其治疗效果.
主要方法:
- 在高血糖和高血糖条件下对小鼠小岛进行了miRNA芯片分析,以识别针对PGC-1α的miRNA.
- 路西法酶记者测定用于确认PGC-1α.的3'-未翻译区域 (3' UTR) 的miR-374结合位.
- 通过腺病毒介导的miR-374和封装miR-374的exendin-4涂层阴离子脂颗粒 (Ex-4-CCL) 在db/db小鼠和胰岛素生成细胞中用于体内和体外评估.
主要成果:
- 确定了miR-374作为一个关键的miRNA,抑制了β细胞和肝细胞中的PGC-1α表达.
- 在db/db小鼠中通过腺病毒介导的miR-374的输送改善了血糖控制,增强了胰岛素分泌,并降低了与肝脏葡萄糖生成相关的基因的调节.
- Ex-4-CCL-miR-374显示,高血糖症显著缓解,胰腺小岛功能恢复,并在暴露于葡萄糖毒性的细胞中改善胰岛素分泌.
结论:
- miR-374通过向PGC-1α.有效地改善高血糖症.
- 在T2DM中,Ex-4-CCL-miR-374代表了扭转β细胞功能障碍和改善肝脏胰岛素耐药性的有前途的治疗策略.
- 向miR-374为2型糖尿病管理提供了一种新的方法.
更多相关视频
07:01Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
Published on: May 10, 2022
1.9K
09:20An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function
Published on: May 4, 2021
4.2K
相关概念视频
Cell Specific Gene Expression
16.2K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
16.2K
Dipeptidyl Peptidase 4 Inhibitors
574
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
574
Glucagon-like Receptor Agonists
832
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
832
MicroRNAs
3.8K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.8K
